Tuesday, December 30, 2014

TSEAC USA Reason For Recalls Blood products, collected from a donors considered to be at increased risk for Creutzfeldt-Jakob Disease (CJD), were distributed END OF YEAR REPORT 2014

Enforcement Report - Week of December 24,

 

FDA Home3 Enforcement Reports

 

4 -

 

Product Detail

 

Product Description Red Blood Cells Leukocytes Reduced

 

Recall Number B-0139-15

 

Classification Class II

 

Code Info W040813110844;

 

Product Distributed Qty 1

 

Reason For Recall Blood products, collected from a donor considered to be at increased risk for Creutzfeldt-Jakob Disease (CJD), were distributed.

 

Event Detail

 

Event Id 69562

 

Product Type Biologics

 

Status Terminated

 

Recalling Firm West TN Regional Blood Ctr, Inc dba Lifeline Blood Services

 

City Jackson

 

State TN

 

Country US

 

Voluntary / Mandated Voluntary: Firm Initiated

 

Recall Initiation

 

Date 2014-10-02

 

Initial Firm Notification of Consignee or Public Letter

 

Distribution Pattern Tennessee; Switzerland

 


 


 

Enforcement Report - Week of December 10, 2014

 

FDA Home3 Enforcement Reports4 -

 

Product Detail

 

Product Description Red Blood Cells Leukocytes Reduced

 

Recall Number B-0144-15

 

Classification Class II

 

Code Info W069114182541

 

Product Distributed Qty 1 unit

 

Reason For Recall Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed.

 

Event Detail

 

Event Id 69503

 

Product Type Biologics

 

Status Terminated Recalling Firm Mississippi Blood Services Inc.

 

City Flowood

 

State MS

 

Country US

 

Voluntary / Mandated Voluntary: Firm Initiated

 

Recall Initiation Date 2014-08-13

 

Initial Firm Notification of Consignee or Public FAX

 

Distribution Pattern Switzerland; MS

 


 


 

those were the weeks of December 2014 ONLY, up to the 24 of December 2014. you can see the other previous weeks, in the months before, and recalls if you search. more breaches of blood safety protocols for the TSE Prion disease here ;

 


 

VERY IMPORTANT SCIENTIFIC FINDINGS HERE ;

 

Wednesday, December 11, 2013

 

*** Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease ***

 


 

*** HUMAN MAD COW DISEASE nvCJD TEXAS CASE NOT LINKED TO EUROPEAN TRAVEL CDC ***

 

Sunday, November 23, 2014

 

*** Confirmed Variant Creutzfeldt-Jakob Disease (variant CJD) Case in Texas in June 2014 confirmed as USA case NOT European ***

 

the patient had resided in Kuwait, Russia and Lebanon. The completed investigation did not support the patient's having had extended travel to European countries, including the United Kingdom, or travel to Saudi Arabia. The specific overseas country where this patient’s infection occurred is less clear largely because the investigation did not definitely link him to a country where other known vCJD cases likely had been infected.

 


 

Sunday, December 14, 2014

 

*** ALERT new variant Creutzfeldt Jakob Disease nvCJD or vCJD, sporadic CJD strains, TSE prion aka Mad Cow Disease United States of America Update December 14, 2014 Report ***

 


 

UPDATE* NOVEMBER 16, 2014 vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???

 

Friday, January 10, 2014

 

Greetings again Friends, Neighbors, and Colleagues,

 

I would kindly like to follow up on ‘vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???’ ran across an old paper from 1984, that some might find interest in, and I will update the link with this old science paper from 1984, a 2010 paper from Japan, and some information on scrapie transmission. The paper from Japan first, then the 1984 paper, and then the scrapie transmission studies.

 

***The occurrence of contact cases raises the possibility that transmission in families may be effected by an unusually virulent strain of the agent.

 


 

From: Terry S. Singeltary Sr.

 

Sent: Saturday, November 15, 2014 9:29 PM

 

To: Terry S. Singeltary Sr.

 

Subject: THE EPIDEMIOLOGY OF CREUTZFELDT-JAKOB DISEASE R. G. WILL 1984

 

THE EPIDEMIOLOGY OF CREUTZFELDT-JAKOB DISEASE

 

R. G. WILL

 

1984

 

snip...

 


 

Friday, January 10, 2014

 

vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???

 


 

Sunday, April 06, 2014

 

SPORADIC CJD and the potential for zoonotic transmission there from, either directly or indirectly via friendly fire iatrogenic mode, evidence to date

 


 

Friday, January 10, 2014

 

vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???

 


 

Sunday, June 29, 2014

 

Transmissible Spongiform Encephalopathy TSE Prion Disease North America 2014

 


 

Transmissible Spongiform Encephalopathy TSE Prion BSE, Scrapie, CWD typical and atypical end of year roundup 2014

 

Sunday, December 21, 2014

 

Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease

 


 

Sunday, December 28, 2014

 

CHRONIC WASTING DISEASE CWD TSE PRION DISEASE AKA MAD DEER DISIEASE USDA USAHA INC DECEMBER 28, 2014

 


 

Wednesday, December 24, 2014

 

National Scrapie Eradication Program November 2014 Monthly Report Fiscal Year 2015

 


 

>>>***>>>Here we show that a panel of sheep scrapie prions transmit to several tgHu mice models with an efficiency comparable to that of cattle BSE. The serial transmission of different scrapie isolates in these mice led to the propagation of prions that are phenotypically identical to those causing sporadic CJD (sCJD) in humans. These results demonstrate that scrapie prions have a zoonotic potential and raise new questions about the possible link between animal and human prions. <<<***<<<

 

Tuesday, December 16, 2014

 

Evidence for zoonotic potential of ovine scrapie prions

 

Hervé Cassard,1, n1 Juan-Maria Torres,2, n1 Caroline Lacroux,1, Jean-Yves Douet,1, Sylvie L. Benestad,3, Frédéric Lantier,4, Séverine Lugan,1, Isabelle Lantier,4, Pierrette Costes,1, Naima Aron,1, Fabienne Reine,5, Laetitia Herzog,5, Juan-Carlos Espinosa,2, Vincent Beringue5, & Olivier Andréoletti1, Affiliations Contributions Corresponding author Journal name: Nature Communications Volume: 5, Article number: 5821 DOI: doi:10.1038/ncomms6821 Received 07 August 2014 Accepted 10 November 2014 Published 16 December 2014 Article tools Citation Reprints Rights & permissions Article metrics

 

Abstract

 

Although Bovine Spongiform Encephalopathy (BSE) is the cause of variant Creutzfeldt Jakob disease (vCJD) in humans, the zoonotic potential of scrapie prions remains unknown. Mice genetically engineered to overexpress the human ​prion protein (tgHu) have emerged as highly relevant models for gauging the capacity of prions to transmit to humans. These models can propagate human prions without any apparent transmission barrier and have been used used to confirm the zoonotic ability of BSE. Here we show that a panel of sheep scrapie prions transmit to several tgHu mice models with an efficiency comparable to that of cattle BSE. The serial transmission of different scrapie isolates in these mice led to the propagation of prions that are phenotypically identical to those causing sporadic CJD (sCJD) in humans. These results demonstrate that scrapie prions have a zoonotic potential and raise new questions about the possible link between animal and human prions.

 

Subject terms: Biological sciences• Medical research At a glance

 


 

see more here ;

 


 

2001

 

Suspect symptoms

 

What if you can catch old-fashioned CJD by eating meat from a sheep infected with scrapie?

 

28 Mar 01

 

Most doctors believe that sCJD is caused by a prion protein deforming by chance into a killer. But Singeltary thinks otherwise. He is one of a number of campaigners who say that some sCJD, like the variant CJD related to BSE, is caused by eating meat from infected animals. Their suspicions have focused on sheep carrying scrapie, a BSE-like disease that is widespread in flocks across Europe and North America.

 

Now scientists in France have stumbled across new evidence that adds weight to the campaigners' fears. To their complete surprise, the researchers found that one strain of scrapie causes the same brain damage in mice as sCJD.

 

"This means we cannot rule out that at least some sCJD may be caused by some strains of scrapie," says team member Jean-Philippe Deslys of the French Atomic Energy Commission's medical research laboratory in Fontenay-aux-Roses, south-west of Paris. Hans Kretschmar of the University of Göttingen, who coordinates CJD surveillance in Germany, is so concerned by the findings that he now wants to trawl back through past sCJD cases to see if any might have been caused by eating infected mutton or lamb...

 

2001

 

Suspect symptoms

 

What if you can catch old-fashioned CJD by eating meat from a sheep infected with scrapie?

 

28 Mar 01

 

Like lambs to the slaughter

 

31 March 2001

 

by Debora MacKenzie Magazine issue 2284.

 

FOUR years ago, Terry Singeltary watched his mother die horribly from a degenerative brain disease. Doctors told him it was Alzheimer's, but Singeltary was suspicious. The diagnosis didn't fit her violent symptoms, and he demanded an autopsy. It showed she had died of sporadic Creutzfeldt-Jakob disease.

 

Most doctors believe that sCJD is caused by a prion protein deforming by chance into a killer. But Singeltary thinks otherwise. He is one of a number of campaigners who say that some sCJD, like the variant CJD related to BSE, is caused by eating meat from infected animals. Their suspicions have focused on sheep carrying scrapie, a BSE-like disease that is widespread in flocks across Europe and North America.

 

Now scientists in France have stumbled across new evidence that adds weight to the campaigners' fears. To their complete surprise, the researchers found that one strain of scrapie causes the same brain damage in mice as sCJD.

 

"This means we cannot rule out that at least some sCJD may be caused by some strains of scrapie," says team member Jean-Philippe Deslys of the French Atomic Energy Commission's medical research laboratory in Fontenay-aux-Roses, south-west of Paris. Hans Kretschmar of the University of Göttingen, who coordinates CJD surveillance in Germany, is so concerned by the findings that he now wants to trawl back through past sCJD cases to see if any might have been caused by eating infected mutton or lamb. ...snip...end

 

see more here ;

 


 


 

Tuesday, December 23, 2014

 

*** FDA PART 589 -- SUBSTANCES PROHIBITED FROM USE IN ANIMAL FOOD OR FEED VIOLATIONS OFFICIAL ACTION INDICATED OAI UPDATE DECEMBER 2014 BSE TSE PRION ***

 


 

Sunday, December 28, 2014

 

*** Reverse Freedom of Information Act request rFOIA FSIS USDA APHIS TSE PRION aka BSE MAD COW TYPE DISEASE December 2014 ***

 


 

Friday, December 19, 2014

 

Rancho Alleged Cancerous Eyeball Case Going To Trial

 


 

Saturday, June 14, 2014

 

Rep. Rosa DeLauro (D-CT) Calls for Briefing on Beef Recalled for Mad Cow Potential Rep. Rosa DeLauro (D-CT)

 


 

Monday, July 28, 2014

 

Mitigating the Risk of Transmission and Environmental Contamination of Transmissible Spongiform Encephalopathies 2013 Annual Report

 


 

Tuesday, August 12, 2014

 

MAD COW USDA TSE PRION COVER UP or JUST IGNORANCE, for the record AUGUST 2014

 


 

Risk of infecting surgery patients with CJD not taken seriously, say MPs

 

Ministers accused of complacency over hospital safeguards to prevent contamination of instruments with human form of BSE

 


 

Wednesday, July 23, 2014

 

*** After the storm? UK blood safety and the risk of variant Creutzfeldt-Jakob Disease ***

 


 

 

*** USA Recall Blood products, collected from a donors who were at risk for variant Creutzfeldt-Jakob disease (vCJD), that were distributed  ***

 

 

Thursday, August 21, 2014

 

FDA Switzerland Reason For Recall Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), was distributed 2014-05-16

 


 

 

Transmissible Spongiform Encephalopathies Advisory Committee TSEAC

 

 

Greetings Bloodcjd and CJDvoice,

 

STILL NO SCHEDULING FOR ANY TSEAC MEETINGS FOR 2014, AND OR THE COMING YEAR OF 2015, out of sight, out of mind, the silence is deafening. ...TSS

 

‘’The Advisory Committee Calendar can be found here: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm We are not able to provide information on meeting dates beyond those listed on the calendar.’’

 

see roster here ;

 


 

 

now, I was told that the TSEAC still exist ;

 

 

Transmissible Spongiform Encephalopathies Advisory Committee


The Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) reviews and evaluates available scientific data concerning the safety of products which may be at risk for transmission of spongiform encephalopathies having an impact on the public health as determined by the Commissioner of Food and Drugs.

The Committee shall consist of a core of 15 voting members, including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of clinical and administrative medicine, hematology, virology, neurovirology, neurology, infectious diseases, immunology, transfusion medicine, surgery, internal medicine, biochemistry, biostatistics, epidemiology, biological and physical sciences, sociology/ethics, and other related professions.



 

 


 

 

I guess they are only meeting every two years now...tss

 

 

Sunday, March 09, 2014

 

A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease

 

FDA TSEAC CIRCUS AND TRAVELING ROAD SHOW FOR THE TSE PRION DISEASES

 


 

Sunday, June 9, 2013

 

TSEAC March 14, 2013: Transmissible Spongiform Encephalopathies Advisory Committee Meeting Webcast

 


 

Monday, May 6, 2013

 

Warning of mad cow disease threat to blood transfusions

 


 

Tuesday, April 30, 2013

 

Mad cow infected blood 'to kill 1,000’

 


 

Sunday, February 10, 2013

 

Creutzfeldt-Jakob disease (CJD) biannual update (February 2013) Infection report/CJD

 


 

Tuesday, May 28, 2013

 

Late-in-life surgery associated with Creutzfeldt-Jakob disease: a methodological outline for evidence-based guidance

 


 

Wednesday, June 29, 2011

 

TSEAC Meeting August 1, 2011 donor deferral Saudi Arabia vCJD risk blood and blood products

 


 

Wednesday, June 29, 2011 TSEAC JUNE 2, 1999 Welcome to the FDA traveling road show From: TSS

 

Subject: TSEAC JUNE 2, 1999 Welcome to the FDA traveling road show

 

Date: October 15, 2007 at 3:18 pm PST

 

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING Thursday, June 2, 1999

 


 

Wednesday, March 2, 2011

 

Transmissible Spongiform Encephalopathies Advisory Committee Meeting Transcript Posted: 3/2/2011 Posted: 3/2/2011

 

October 28, 2010

 

Transmissible Spongiform Encephalopathies Advisory Committee Meeting Transcript Posted: 3/2/2011

 


 

Monday, February 7, 2011

 

FDA’s Currently-Recommended Policies to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products 2011 ???

 


 

October 29, 2010

 

Transmissible Spongiform Encephalopathies Advisory Committee Meeting Transcript Posted: 3/2/2011

 


 

Monday, October 18, 2010

 

TSEAC Transmissible Spongiform Encephalopathies Advisory Committee Draft Agenda and Meeting Materials,

 

Posted: 10/18/2010

 

Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee Center Date Time Location

 


 

Tuesday, September 14, 2010

 

Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting October 28 and 29, 2010 (COMMENT SUBMISSION)

 


 

Saturday, September 5, 2009

 

TSEAC MEETING FEBRUARY 12, 2004 THE BAXTER STUDY GSS

 


 

Sunday, May 10, 2009

 

Meeting of the Transmissible Spongiform Encephalopathies Committee On June 12, 2009 (Singeltary submission)

 

TO : william.freas@fda.hhs.gov

 

May 8, 2009

 

Greetings again Dr. Freas, TSEAC et al,

 

I would kindly, once again, wish to comment at this meeting about the urgent actions that need to be taken asap, to the Meeting of the Transmissible Spongiform Encephalopathies Committee On June 12, 2009. Due to my disability from my neck injury, I will not be attending this meeting either, however I hope for my submission to be read and submitted. ...

 

IN reply to ;

 


 

snip...see full text ;

 

Sunday, May 10, 2009

 

Meeting of the Transmissible Spongiform Encephalopathies Committee On June 12, 2009 (Singeltary submission)

 

TO : william.freas@fda.hhs.gov

 


 

Harvard Risk Assessment of Bovine Spongiform Encephalopathy Update, October 31, 2005 INTRODUCTION The United States Department of Agriculture’s Food Safety and Inspection Service (FSIS) held a public meeting on July 25, 2006 in Washington, D.C. to present findings from the Harvard Risk Assessment of Bovine Spongiform Encephalopathy Update, October 31, 2005 (report and model located on the FSIS website:

 


 

Comments on technical aspects of the risk assessment were then submitted to FSIS. Comments were received from Food and Water Watch, Food Animal Concerns Trust (FACT), Farm Sanctuary, R-CALF USA, Linda A Detwiler, and Terry S. Singeltary. This document provides itemized replies to the public comments received on the 2005 updated Harvard BSE risk assessment. Please bear the following points in mind:

 


 

From: Terry S. Singeltary Sr.

 

To: FREAS@CBER.FDA.GOV

 

Cc: william.freas@fda.hhs.gov ; rosanna.harvey@fda.hhs.gov

 

Sent: Friday, December 01, 2006 2:59 PM

 

Subject: Re: TSE advisory committee for the meeting December 15, 2006 [TSS SUBMISSION

 

snip...

 

ONE FINAL COMMENT PLEASE, (i know this is long Dr. Freas but please bear with me)

 

THE USA is in a most unique situation, one of unknown circumstances with human and animal TSE. THE USA has the most documented TSE in different species to date, with substrains growing in those species (BSE/BASE in cattle and CWD in deer and elk, there is evidence here with different strains), and we know that sheep scrapie has over 20 strains of the typical scrapie with atypical scrapie documented and also BSE is very likely to have passed to sheep. all of which have been rendered and fed back to animals for human and animal consumption, a frightening scenario. WE do not know the outcome, and to play with human life around the globe with the very likely TSE tainted blood from the USA, in my opinion is like playing Russian roulette, of long duration, with potential long and enduring consequences, of which once done, cannot be undone.

 

These are the facts as i have come to know through daily and extensive research of TSE over 9 years, since 12/14/97. I do not pretend to have all the answers, but i do know to continue to believe in the ukbsenvcjd only theory of transmission to humans of only this one strain from only this one TSE from only this one part of the globe, will only lead to further failures, and needless exposure to humans from all strains of TSE, and possibly many more needless deaths from TSE via a multitude of proven routes and sources via many studies with primates and rodents and other species. ...

 

Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518

 

snip... 48 pages...

 


 

Wednesday, October 17, 2007 TSEAC MEETINGS ----- Original Message -----

 

From: Terry S. Singeltary Sr.

 

To: FREAS@CBER.FDA.GOV

 

Cc: william.freas@fda.hhs.gov ; rosanna.harvey@fda.hhs.gov

 

Sent: Wednesday, November 29, 2006 1:24 PM

 

Subject: TSE advisory committee for the meeting December 15, 2006 [TSSSUBMISSION]November 29, 2006

 

Greetings FDA, DHH, Dr. Freas, and Dr. Harvey et al,

 

a kind and warm Holiday Greetings to you all.i kindly wish to submit the following to the TSE advisory committee for the meeting December 15, 2006, about the assessment for potential exposure to vCJD in human plasma-derivedantihemophilic factor (FVIII) productsmanufactured from U.S. plasma donors and related communication material ;

 


 

i see the media picked up on this as a 'low risk', from what the gov. agency perceived to be to them;

 


 

however, i seem to disagree. from my primitive ciphering, i see it another way. this is a huge catastrophic risk. 3 in 160 is 1.9%. so call that 2% which is 1 in 50 or twenty per thousand or 20,000 per million. also, wha tabout the mixed genotypes/mixed susceptibility?

 

what about the silent carriers that donated tainted blood?

 

what about the sporadic CJDs of UNKNOWN strain or phenotype?

 

this risk assessment is just more BSe to me. just another in a long line of industry fed crap. i pray that my assessment is the one that is wrong. but it is THEY who roll the dice with your life. it is THEY who refuse to regulate an industry that has run amok. just from are call aspect of potentially tainted blood, and these are just recent recalls ;

 

PRODUCT

 

Source Plasma, Recall # B-0054-7CODEUnits: 03MMNC5465, 03MMNC6361, 03MMNC6801, 03MMNC7510, 03MMNC7891,03MMNC8252, 03MMNC8801, 03MMNC9144, 03MMND1122, 03MMND1478, 03MMND1969,03MMND2350, 03MMND2825, 03MMND3211, 03MMND3708, 03MMND4072, 03MMND4588,03MMND4831, 03MMND5320, 03MMND5719, 03MMND6268, 03MMND6683, 03MMND7228,03MMND7656, 03MMND8211, 03MMND8652, 03MMND9195, 03MMND9618, 03MMNE0628,03MMNE0884, 03MMNE1597, 03MMNE1979, 03MMNE2644, 03MMNE3064, 03MMNE3707,03MMNE4122, 03MMNE4750, 03MMNE5080, 03MMNE5876, 03MMNE6218, 03MMNE7189,03MMNE7587, 03MMNE8027, 03MMNE8645, 03MMNE9029, 03MMNE9641, 03MMNE9979,03MMNF0491, 03MMNF0685, 03MMNF0937, 03MMNF1260, 04MMNA0351, 04MMNA0707,04MMNA1241, 04MMNA1650, 04MMNA2291, 04MMNA2646, 04MMNA3340, 04MMNA3719,04MMNA4312, 04MMNA4683, 04MMNA5298, 04MMNA5750, 04MMNA6407, 04MMNA6816,04MMNA7482, 04MMNA7915, 04MMNA8632, 04MMNA9076, 04MMNA9723, 04MMNB0063,04MMNB0696, 04MMNB1100, 04MMNB1845, 04MMNB2285, 04MMNB3035, 04MMNB3485,04MMNB4213, 04MMNB4672, 04MMNB5841, 04MMNB6652, 04MMNB7162, 04MMNB7930,04MMNB8453, 04MMNB9239, 04MMNB9747, 04MMNC0456, 04MMNC0931, 04MMNC1578

 

RECALLING FIRM/MANUFACTURER

 

BioLife Plasma Services, L.P., Mankato, MN, by facsimile on June 4, 2004.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who was at increased risk for new variant Creutzfeldt-Jakob Disease (nvCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

89 units

 

DISTRIBUTION

 

CA and Austria

 

END OF ENFORCEMENT REPORT FOR October 25, 2006

 

###

 


 

USA FDA MAD COW BLOOD HUMANS RECALL (these are dime a dozen)RECALLS AND FIELD CORRECTIONS: BIOLOGICS -- CLASS II

 

______________________________

 

PRODUCTSource Plasma, Recall # B-1708-6CODEUnits: MI180733, MI180927, MI181625, MI181780, MI182337, MI182519, MI183140,MI183311, MI183955, MI185006, MI185278, MI185822, MI186081, MI186855,MI187183, MI187903, MI188273, MI188695, MI189257, MI189553, MI190136,MI190473, MI191073, MI191395, MI191972, MI192303, MI193473, MI194343,04MINA0377, 04MINA0801, 05MINA7147, 05MINA7451, 05MINA8094, 05MINA8504,05MINA9548, 05MINA9883, 05MINB0489, 05MINB0875, 05MINB1469, 05MINB1874,05MINB3116, 05MINB7192, 05MINB7529, 05MINB8246, 05MINB8612, 05MINB9236,05MINB9366, 05MINB9475, 05MINB9641, 05MINC0031, 05MINC0237, 05MINC0336,05MINC0894, 05MINC0964, 05MINC1138, 05MINC1619, 05MINC1750, 05MINC1907,05MINC1977, 05MINC2375, 05MINC2774, 05MINC3113, 05MINC3484, 05MINC4277,05MINC4623, 05MINC5623, 05MINC5914, 05MINC7545, 05MINC7870, 05MINC8355,05MINC8689, 05MINC9437, 05MINC9775, 05MIND0067, 05MIND0393, 05MIND0892,05MIND0951, 05MIND1836, 05MIND2183 and 05MIND2962

 

RECALLING FIRM/MANUFACTURER

 

BioLife Plasma Services L.P., Muncie, IN, by facsimile on November 22, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, collected from unsuitable donors based on risk factors for Creutzfeldt-Jakob Disease (CJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

80 units

 

DISTRIBUTION CA, NC, and MD

 

______________________________

 

PRODUCT

 

a) Red Blood Cells, Leukocytes Reduced, Recall # B-1714-6;b) Fresh Frozen Plasma, Recall # B-1715-6;c) Platelets, Recall # B-1716-6CODEa),

 

b), and c) Unit: 2443732RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by letters dated November 11, 2003 and December 18, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who was at increased risk for new variant Creutzfeldt-Jakob Disease (nvCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and WI

 

END OF ENFORCEMENT REPORT FOR SEPTEMBER 13, 2006

 

###

 


 

PRODUCT

 

Fresh Frozen Plasma, Recall # B-1751-6

 

CODE

 

Unit: 4936623

 

RECALLING FIRM/MANUFACTURER

 

Gulf Coast Regional Blood Center, Houston, TX, by facsimile dated September 16, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood product, which was collected from an unsuitable donor based on risk factors for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

TX

 

END OF ENFORCEMENT REPORT FOR SEPTEMBER 6, 2006

 

###

 


 

Mon Aug 7, 2006 10:2471.248.132.189

 

PRODUCT

 

a) Red Blood Cells, Recall # B-1587-6;b) Cryoprecipitated AHF, Recall # B-1588-6;c) Recovered Plasma, Recal # B-1589-6

 

CODE

 

a), b) and c)

 

Unit: 2016719

 

RECALLING FIRM/MANUFACTURER

 

Walter Shepeard Community Blood Center, Inc., Augusta, GA, by facsimile on March 13, 2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

GA and Germany

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1590-6;b) Fresh Frozen Plasma, Recall # B-1591-6

 

CODE

 

a) and b)

 

Unit: 2443595

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on June30, 2004.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1592-6;b) Fresh Frozen Plasma, Recall # B-1593-6

 

CODEa) and b)

 

Unit: 2545596

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on December 14, 2004 and January 3, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 


 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1550-6;b) Fresh Frozen Plasma, Recall # B-1551-6

 

CODEa) and b)

 

Unit 2395371

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on August 20,2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1552-6;b) Platelets, Recall # B-1553-6;c) Fresh Frozen Plasma, Recall # B-1554-6

 

CODE

 

a), b) and c)

 

Unit 2438702

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on May 29,2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increasedrisk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1555-6;b) Fresh Frozen Plasma, Recall # B-1556-6

 

CODEa) and b)

 

Unit 2454970

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on July 23 and December 11. 2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells, Recall # B-1494-6b) Cryoprecipitated AHF, Recall # B-1495-6

 

CODEa) and b)

 

Unit 5013100

 

RECALLING FIRM/MANUFACTURER

 

Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on May17, 2005. Firm initiated recall is complete.REASONBlood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

GA

 

______________________________

 

PRODUCT

 

Source Plasma, Recall # B-1450-6

 

CODE

 

Unit numbers ST0824313 and ST0824764

 

RECALLING FIRM/MANUFACTURER

 

Stillwater Plasma Center LLC, Stillwater, OK, by fax on November 21, 2003.

 

Firm initiated recall is complete.REASON

 

Blood products, which were collected from a donor whose suitability pertaining to risk factors for Creutzfeldt-Jakob Disease (vCJD) was not adequately determined, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

UK

 

______________________________

 

PRODUCT

 

Plasma Frozen, Recall # B-1422-6;Recovered Plasma, Recall # B-1423-6

 

CODE

 

a) Unit 03E42218;

 

b) Unit 03E38153

 

RECALLING FIRM/MANUFACTURER

 

American Red Cross Blood Services, Atlanta, GA, by telephone, e-mail orletter on February 20 or 21, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

GA and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1374-6;

 

b) Recovered Plasma, Recall # B-1375-6CODEa) and b) unit 2453906

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on October 31 and November 5, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX and Austria

 

______________________________

 

PRODUCT

 

Source Plasma.

 

Recall # B-1295-6

 

CODE

 

Units: NG0046551, NG0045950

 

RECALLING FIRM/MANUFACTURERD

 

CI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002, Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who did not answer the questions on the new variant Creutzfeldt-Jacob disease (nvCJD) questionnaire appropriately, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma. Recall # B-1296-6

 

CODE

 

Unit: NG 0044520RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 12, 2002. Firm initiated recall is complete.

 

REASON

 

Blood product, collected from a donor who did not answer the questions on the new variant Creutzfeldt-Jacob disease (nvCJD) questionnaire, was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma. Recall # B-1297-6

 

CODE

 

Units: NG0042874, NG0043139, NG0043312, NG0043618, NG0043797, NG0044020,NG0044209, NG0044507, NG0044718, NG0044977, NG0045161, NG0045412, NG0045555RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

13 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma, Recall # B-1298-6

 

CODE

 

Units: NG 0046823, NG 0046671, NG 0045205, NG 0044635, NG 0043095, NG0042525, NG 0042341RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who answered questions on the variant Creutzfeldt-Jacob disease (vCJD) questionnaire inappropriately, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

7 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Recovered Plasma, Recall # B-1299-6CODEUnit: 4357117

 

RECALLING FIRM/MANUFACTURER

 

Department of the Navy, Naval Medical Center, San Diego, CA, by fax and letter on September 25, 2003. Firm initiated recall is complete.

 

REASON

 

Blood product, collected from a donor considered to be at risk of exposure to Creutzfeldt-Jacob Disease (CJD), was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

Germany

 

END OF ENFORCEMENT REPORT FOR July 12, 2006

 

###

 


 

CJD WATCH MESSAGE BOARD

 

TSS

 

FDA mad cow nvCJD 'only' blood recalls 1ST WEEK JULY Fri Jul 7, 2006 09:3770.110.83.160

 

FDA mad cow nvCJD 'only' blood recalls 1ST WEEK JULY

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1379-6;

 

b) Platelets, Recall # B-1380-6;

 

c) Fresh Frozen Plasma, Recall # 1381-6;

 

d) Recovered Plasma, Recall # B-1382-6

 

CODE

 

a) Unit numbers: 2343106, 2377779, and 2403533;

 

b) and c) Unit numbers: 2377779;

 

d) Unit numbers: 2343106 and 2403533

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on June12, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

7 units

 

DISTRIBUTIONTX and Austria

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1467-6;

 

b) Recovered Plasma, Recall # B-1468-6

 

CODE

 

a) and b)

 

Unit numbers: 2329380

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on May 8,2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTIONTX and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1479-6;

 

b) Cryoprecipitated AHF, Recall # B-1480-6;

 

c) Recovered Plasma, Recall # B-1481-6

 

CODE

 

a), b), and c)

 

Unit numbers: 2383280

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on July23 and 29, 2004. Firm initiated recall is complete.

 

REASONBlood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1482-6;

 

b) Fresh Frozen Plasma, Recall # B-1483-6

 

CODE

 

a) and b)

 

Unit number: 2501452

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile onOctober 5, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX and NY

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1484-6;

 

b) Plasma Cryoprecipitated Reduced, Recall # B-1485-6;

 

c) Recovered Plasma, Recall # B-1486-6

 

CODE

 

a) and c)

 

Unit number: 2554077;

 

b) Unit number: 2415708

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on August13, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and Austria

 

_____________________________________

 

END OF ENFORCEMENT REPORT FOR July 5, 2006

 

###

 


 

Greetings again Dr. Freas et al at FDA,

 

WITH new atypical TSE in the bovine, in the sheep, goat, and humans, and the fact that the new BASE TSE in cattle being very very similar to sporadic CJD, rather than the nvCJD, the fact that now science showing the TSE agent of the atypical cattle in Japan showing infectivity other than CNS tissue, the fact that the latest Texas mad cow and the recent Alabama mad cow both being of the atypical strain, it would seem prudent to include all human TSE in the blood ban, in my opinion. with sporadic CJD, you have many strains and or phenotypes, some of which are 'UNKNOWN', so we do not know how this will transmit, what tissues are infectious and or if blood transmits. that's the bottomline, however it has been reported that the BASE is more virulent to humans.With this, and the fact that sporadic CJD has tripled in the past few years or so, i see itas being prudent to take serious and immediate action ;

 

snip...see full text ;

 

Wednesday, October 17, 2007 TSEAC MEETINGS ----- Original Message -----

 

From: Terry S. Singeltary Sr.

 

To: FREAS@CBER.FDA.GOV

 

Cc: william.freas@fda.hhs.gov ; rosanna.harvey@fda.hhs.gov

 

Sent: Wednesday, November 29, 2006 1:24 PM

 

Subject: TSE advisory committee for the meeting December 15, 2006 [TSSSUBMISSION]November 29, 2006

 

Greetings FDA, DHH, Dr. Freas, and Dr. Harvey et al,

 

a kind and warm Holiday Greetings to you all.i kindly wish to submit the following to the TSE advisory committee for the meeting December 15, 2006, about the assessment for potential exposure to vCJD in human plasma-derivedantihemophilic factor (FVIII) productsmanufactured from U.S. plasma donors and related communication material ;

 


 

i see the media picked up on this as a 'low risk', from what the gov. agency perceived to be to them;

 


 

however, i seem to disagree. from my primitive ciphering, i see it another way. this is a huge catastrophic risk. 3 in 160 is 1.9%. so call that 2% which is 1 in 50 or twenty per thousand or 20,000 per million. also, wha tabout the mixed genotypes/mixed susceptibility?

 

what about the silent carriers that donated tainted blood?

 

what about the sporadic CJDs of UNKNOWN strain or phenotype?

 

this risk assessment is just more BSe to me. just another in a long line of industry fed crap. i pray that my assessment is the one that is wrong. but it is THEY who roll the dice with your life. it is THEY who refuse to regulate an industry that has run amok. just from are call aspect of potentially tainted blood, and these are just recent recalls ;

 

PRODUCT

 

Source Plasma, Recall # B-0054-7CODEUnits: 03MMNC5465, 03MMNC6361, 03MMNC6801, 03MMNC7510, 03MMNC7891,03MMNC8252, 03MMNC8801, 03MMNC9144, 03MMND1122, 03MMND1478, 03MMND1969,03MMND2350, 03MMND2825, 03MMND3211, 03MMND3708, 03MMND4072, 03MMND4588,03MMND4831, 03MMND5320, 03MMND5719, 03MMND6268, 03MMND6683, 03MMND7228,03MMND7656, 03MMND8211, 03MMND8652, 03MMND9195, 03MMND9618, 03MMNE0628,03MMNE0884, 03MMNE1597, 03MMNE1979, 03MMNE2644, 03MMNE3064, 03MMNE3707,03MMNE4122, 03MMNE4750, 03MMNE5080, 03MMNE5876, 03MMNE6218, 03MMNE7189,03MMNE7587, 03MMNE8027, 03MMNE8645, 03MMNE9029, 03MMNE9641, 03MMNE9979,03MMNF0491, 03MMNF0685, 03MMNF0937, 03MMNF1260, 04MMNA0351, 04MMNA0707,04MMNA1241, 04MMNA1650, 04MMNA2291, 04MMNA2646, 04MMNA3340, 04MMNA3719,04MMNA4312, 04MMNA4683, 04MMNA5298, 04MMNA5750, 04MMNA6407, 04MMNA6816,04MMNA7482, 04MMNA7915, 04MMNA8632, 04MMNA9076, 04MMNA9723, 04MMNB0063,04MMNB0696, 04MMNB1100, 04MMNB1845, 04MMNB2285, 04MMNB3035, 04MMNB3485,04MMNB4213, 04MMNB4672, 04MMNB5841, 04MMNB6652, 04MMNB7162, 04MMNB7930,04MMNB8453, 04MMNB9239, 04MMNB9747, 04MMNC0456, 04MMNC0931, 04MMNC1578

 

RECALLING FIRM/MANUFACTURER

 

BioLife Plasma Services, L.P., Mankato, MN, by facsimile on June 4, 2004.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who was at increased risk for new variant Creutzfeldt-Jakob Disease (nvCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

89 units

 

DISTRIBUTION

 

CA and Austria

 

END OF ENFORCEMENT REPORT FOR October 25, 2006

 

###

 


 

USA FDA MAD COW BLOOD HUMANS RECALL (these are dime a dozen)RECALLS AND FIELD CORRECTIONS: BIOLOGICS -- CLASS II

 

______________________________

 

PRODUCTSource Plasma, Recall # B-1708-6CODEUnits: MI180733, MI180927, MI181625, MI181780, MI182337, MI182519, MI183140,MI183311, MI183955, MI185006, MI185278, MI185822, MI186081, MI186855,MI187183, MI187903, MI188273, MI188695, MI189257, MI189553, MI190136,MI190473, MI191073, MI191395, MI191972, MI192303, MI193473, MI194343,04MINA0377, 04MINA0801, 05MINA7147, 05MINA7451, 05MINA8094, 05MINA8504,05MINA9548, 05MINA9883, 05MINB0489, 05MINB0875, 05MINB1469, 05MINB1874,05MINB3116, 05MINB7192, 05MINB7529, 05MINB8246, 05MINB8612, 05MINB9236,05MINB9366, 05MINB9475, 05MINB9641, 05MINC0031, 05MINC0237, 05MINC0336,05MINC0894, 05MINC0964, 05MINC1138, 05MINC1619, 05MINC1750, 05MINC1907,05MINC1977, 05MINC2375, 05MINC2774, 05MINC3113, 05MINC3484, 05MINC4277,05MINC4623, 05MINC5623, 05MINC5914, 05MINC7545, 05MINC7870, 05MINC8355,05MINC8689, 05MINC9437, 05MINC9775, 05MIND0067, 05MIND0393, 05MIND0892,05MIND0951, 05MIND1836, 05MIND2183 and 05MIND2962

 

RECALLING FIRM/MANUFACTURER

 

BioLife Plasma Services L.P., Muncie, IN, by facsimile on November 22, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, collected from unsuitable donors based on risk factors for Creutzfeldt-Jakob Disease (CJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

80 units

 

DISTRIBUTION CA, NC, and MD

 

______________________________

 

PRODUCT

 

a) Red Blood Cells, Leukocytes Reduced, Recall # B-1714-6;b) Fresh Frozen Plasma, Recall # B-1715-6;c) Platelets, Recall # B-1716-6CODEa),

 

b), and c) Unit: 2443732RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by letters dated November 11, 2003 and December 18, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who was at increased risk for new variant Creutzfeldt-Jakob Disease (nvCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and WI

 

END OF ENFORCEMENT REPORT FOR SEPTEMBER 13, 2006

 

###

 


 

PRODUCT

 

Fresh Frozen Plasma, Recall # B-1751-6

 

CODE

 

Unit: 4936623

 

RECALLING FIRM/MANUFACTURER

 

Gulf Coast Regional Blood Center, Houston, TX, by facsimile dated September 16, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood product, which was collected from an unsuitable donor based on risk factors for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

TX

 

END OF ENFORCEMENT REPORT FOR SEPTEMBER 6, 2006

 

###

 


 

Mon Aug 7, 2006 10:2471.248.132.189

 

PRODUCT

 

a) Red Blood Cells, Recall # B-1587-6;b) Cryoprecipitated AHF, Recall # B-1588-6;c) Recovered Plasma, Recal # B-1589-6

 

CODE

 

a), b) and c)

 

Unit: 2016719

 

RECALLING FIRM/MANUFACTURER

 

Walter Shepeard Community Blood Center, Inc., Augusta, GA, by facsimile on March 13, 2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

GA and Germany

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1590-6;b) Fresh Frozen Plasma, Recall # B-1591-6

 

CODE

 

a) and b)

 

Unit: 2443595

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on June30, 2004.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1592-6;b) Fresh Frozen Plasma, Recall # B-1593-6

 

CODEa) and b)

 

Unit: 2545596

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on December 14, 2004 and January 3, 2005.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 


 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1550-6;b) Fresh Frozen Plasma, Recall # B-1551-6

 

CODEa) and b)

 

Unit 2395371

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on August 20,2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1552-6;b) Platelets, Recall # B-1553-6;c) Fresh Frozen Plasma, Recall # B-1554-6

 

CODE

 

a), b) and c)

 

Unit 2438702

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on May 29,2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increasedrisk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1555-6;b) Fresh Frozen Plasma, Recall # B-1556-6

 

CODEa) and b)

 

Unit 2454970

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on July 23 and December 11. 2003.

 

Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX

 

______________________________

 

PRODUCT

 

a) Red Blood Cells, Recall # B-1494-6b) Cryoprecipitated AHF, Recall # B-1495-6

 

CODEa) and b)

 

Unit 5013100

 

RECALLING FIRM/MANUFACTURER

 

Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on May17, 2005. Firm initiated recall is complete.REASONBlood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

GA

 

______________________________

 

PRODUCT

 

Source Plasma, Recall # B-1450-6

 

CODE

 

Unit numbers ST0824313 and ST0824764

 

RECALLING FIRM/MANUFACTURER

 

Stillwater Plasma Center LLC, Stillwater, OK, by fax on November 21, 2003.

 

Firm initiated recall is complete.REASON

 

Blood products, which were collected from a donor whose suitability pertaining to risk factors for Creutzfeldt-Jakob Disease (vCJD) was not adequately determined, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

UK

 

______________________________

 

PRODUCT

 

Plasma Frozen, Recall # B-1422-6;Recovered Plasma, Recall # B-1423-6

 

CODE

 

a) Unit 03E42218;

 

b) Unit 03E38153

 

RECALLING FIRM/MANUFACTURER

 

American Red Cross Blood Services, Atlanta, GA, by telephone, e-mail orletter on February 20 or 21, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

GA and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1374-6;

 

b) Recovered Plasma, Recall # B-1375-6CODEa) and b) unit 2453906

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by fax on October 31 and November 5, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX and Austria

 

______________________________

 

PRODUCT

 

Source Plasma.

 

Recall # B-1295-6

 

CODE

 

Units: NG0046551, NG0045950

 

RECALLING FIRM/MANUFACTURERD

 

CI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002, Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who did not answer the questions on the new variant Creutzfeldt-Jacob disease (nvCJD) questionnaire appropriately, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma. Recall # B-1296-6

 

CODE

 

Unit: NG 0044520RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 12, 2002. Firm initiated recall is complete.

 

REASON

 

Blood product, collected from a donor who did not answer the questions on the new variant Creutzfeldt-Jacob disease (nvCJD) questionnaire, was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma. Recall # B-1297-6

 

CODE

 

Units: NG0042874, NG0043139, NG0043312, NG0043618, NG0043797, NG0044020,NG0044209, NG0044507, NG0044718, NG0044977, NG0045161, NG0045412, NG0045555RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

13 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Source Plasma, Recall # B-1298-6

 

CODE

 

Units: NG 0046823, NG 0046671, NG 0045205, NG 0044635, NG 0043095, NG0042525, NG 0042341RECALLING FIRM/MANUFACTURERDCI Biologicals Nacogdoches LLC, Nacogdoches, TX, by telephone and fax onDecember 20, 2002. Firm initiated recall is complete.

 

REASON

 

Blood products, collected from a donor who answered questions on the variant Creutzfeldt-Jacob disease (vCJD) questionnaire inappropriately, were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

7 units

 

DISTRIBUTION

 

KY

 

______________________________

 

PRODUCT

 

Recovered Plasma, Recall # B-1299-6CODEUnit: 4357117

 

RECALLING FIRM/MANUFACTURER

 

Department of the Navy, Naval Medical Center, San Diego, CA, by fax and letter on September 25, 2003. Firm initiated recall is complete.

 

REASON

 

Blood product, collected from a donor considered to be at risk of exposure to Creutzfeldt-Jacob Disease (CJD), was distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

1 unit

 

DISTRIBUTION

 

Germany

 

END OF ENFORCEMENT REPORT FOR July 12, 2006

 

###

 


 

CJD WATCH MESSAGE BOARD

 

TSS

 

FDA mad cow nvCJD 'only' blood recalls 1ST WEEK JULY Fri Jul 7, 2006 09:3770.110.83.160

 

FDA mad cow nvCJD 'only' blood recalls 1ST WEEK JULY

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1379-6;

 

b) Platelets, Recall # B-1380-6;

 

c) Fresh Frozen Plasma, Recall # 1381-6;

 

d) Recovered Plasma, Recall # B-1382-6

 

CODE

 

a) Unit numbers: 2343106, 2377779, and 2403533;

 

b) and c) Unit numbers: 2377779;

 

d) Unit numbers: 2343106 and 2403533

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on June12, 2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

7 units

 

DISTRIBUTIONTX and Austria

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1467-6;

 

b) Recovered Plasma, Recall # B-1468-6

 

CODE

 

a) and b)

 

Unit numbers: 2329380

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on May 8,2003. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTIONTX and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1479-6;

 

b) Cryoprecipitated AHF, Recall # B-1480-6;

 

c) Recovered Plasma, Recall # B-1481-6

 

CODE

 

a), b), and c)

 

Unit numbers: 2383280

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on July23 and 29, 2004. Firm initiated recall is complete.

 

REASONBlood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and Switzerland

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1482-6;

 

b) Fresh Frozen Plasma, Recall # B-1483-6

 

CODE

 

a) and b)

 

Unit number: 2501452

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile onOctober 5, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

2 units

 

DISTRIBUTION

 

TX and NY

 

______________________________

 

PRODUCT

 

a) Red Blood Cells Leukocytes Reduced, Recall # B-1484-6;

 

b) Plasma Cryoprecipitated Reduced, Recall # B-1485-6;

 

c) Recovered Plasma, Recall # B-1486-6

 

CODE

 

a) and c)

 

Unit number: 2554077;

 

b) Unit number: 2415708

 

RECALLING FIRM/MANUFACTURER

 

South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on August13, 2004. Firm initiated recall is complete.

 

REASON

 

Blood products, which were collected from a donor who may be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.

 

VOLUME OF PRODUCT IN COMMERCE

 

3 units

 

DISTRIBUTION

 

TX and Austria

 

_____________________________________

 

END OF ENFORCEMENT REPORT FOR July 5, 2006

 

###

 


 

Greetings again Dr. Freas et al at FDA,

 

WITH new atypical TSE in the bovine, in the sheep, goat, and humans, and the fact that the new BASE TSE in cattle being very very similar to sporadic CJD, rather than the nvCJD, the fact that now science showing the TSE agent of the atypical cattle in Japan showing infectivity other than CNS tissue, the fact that the latest Texas mad cow and the recent Alabama mad cow both being of the atypical strain, it would seem prudent to include all human TSE in the blood ban, in my opinion. with sporadic CJD, you have many strains and or phenotypes, some of which are 'UNKNOWN', so we do not know how this will transmit, what tissues are infectious and or if blood transmits. that's the bottomline, however it has been reported that the BASE is more virulent to humans.With this, and the fact that sporadic CJD has tripled in the past few years or so, i see itas being prudent to take serious and immediate action ;

 




2001 Singeltary Submission to FDA on blood related risk factors from TSE prion aka mad cow type disease
 

PDF]Freas, William TSS SUBMISSION

 

File Format: PDF/Adobe Acrobat -

 

Page 1. J Freas, William From: Sent: To: Subject: Terry S. Singeltary

 

Sr. [flounder@wt.net] Monday, January 08,200l 3:03 PM freas ...

 


 

Tuesday, February 8, 2011

 

U.S.A. 50 STATE BSE MAD COW CONFERENCE CALL Jan. 9, 2001

 


 

Thursday, February 24, 2011

 

The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products

 


 

***********CJD REPORT 1994 increased risk for consumption of veal and venison and lamb***********

 

CREUTZFELDT JAKOB DISEASE SURVEILLANCE IN THE UNITED KINGDOM THIRD ANNUAL REPORT AUGUST 1994

 

Consumption of venison and veal was much less widespread among both cases and controls. For both of these meats there was evidence of a trend with increasing frequency of consumption being associated with increasing risk of CJD. (not nvCJD, but sporadic CJD...tss)

 

These associations were largely unchanged when attention was restricted to pairs with data obtained from relatives. ...

 

Table 9 presents the results of an analysis of these data.

 

There is STRONG evidence of an association between ‘’regular’’ veal eating and risk of CJD (p = .0.01).

 

Individuals reported to eat veal on average at least once a year appear to be at 13 TIMES THE RISK of individuals who have never eaten veal.

 

There is, however, a very wide confidence interval around this estimate. There is no strong evidence that eating veal less than once per year is associated with increased risk of CJD (p = 0.51).

 

The association between venison eating and risk of CJD shows similar pattern, with regular venison eating associated with a 9 FOLD INCREASE IN RISK OF CJD (p = 0.04).

 

There is some evidence that risk of CJD INCREASES WITH INCREASING FREQUENCY OF LAMB EATING (p = 0.02).

 

The evidence for such an association between beef eating and CJD is weaker (p = 0.14). When only controls for whom a relative was interviewed are included, this evidence becomes a little STRONGER (p = 0.08).

 

snip...

 

It was found that when veal was included in the model with another exposure, the association between veal and CJD remained statistically significant (p = < 0.05 for all exposures), while the other exposures ceased to be statistically significant (p = > 0.05).

 

snip...

 

In conclusion, an analysis of dietary histories revealed statistical associations between various meats/animal products and INCREASED RISK OF CJD. When some account was taken of possible confounding, the association between VEAL EATING AND RISK OF CJD EMERGED AS THE STRONGEST OF THESE ASSOCIATIONS STATISTICALLY. ...

 

snip...

 

In the study in the USA, a range of foodstuffs were associated with an increased risk of CJD, including liver consumption which was associated with an apparent SIX-FOLD INCREASE IN THE RISK OF CJD. By comparing the data from 3 studies in relation to this particular dietary factor, the risk of liver consumption became non-significant with an odds ratio of 1.2 (PERSONAL COMMUNICATION, PROFESSOR A. HOFMAN. ERASMUS UNIVERSITY, ROTTERDAM). (???...TSS)

 

snip...see full report ;

 


 

Thursday, October 10, 2013

 

*************CJD REPORT 1994 increased risk for consumption of veal and venison and lamb**************

 


 

PEO752/2 0097

 

CONFIDENTIAL-POLICY MARKET SENSITIVE-LIMITED DISTRIBUTION

 

BSE AND CJD

 

RECEIVED

 

25 MAR 1996

 

BSE AND CJD

 

The Prime Minister held a meeting on Tuesday 19 March to discuss the latest scientific information on Bovine Spongiform Encephalopathy (BSE) and Creutzfeldt Jacob Disease (CJD), The Deputy Prime Minister, the Lord President, Chief Secretary, Lord Privy Seal, the Secretary of State for Health, the Secretary of State for Scotland, the Minister for Agriculture. the Financial Secretary, the Attorney General, the Minister for Food, the Chief Whip, Sir Robin Butler, Keith Meldrum (Chief Veterinary Officer), Professor Pattison (Chairman of SEAC), Dr Eileen Rubery (Department of Health), Richard Packer (MAFF), Lord McColl, John Ward, Howell James, Alex Allan, Jonathan Haslam, Robert Culpin (HM Treasury), Kenneth Mackenzie (Cabinet Office), Tim Sutton (HM Treasury) were also present.

 

The Deputy Prime Minister, the Chief Secretary to the Treasury and the Lord Privy Seal all announced that they had relevant interests in the form of cattle herds.

 

The Prime Minister began the meeting by commenting that some very difficult decisions needed to be taken to ensure that the correct balance was struck between treating this matter seriously and over-reacting. Colleagues needed to recall that there were many issues which remained unknown.

 

Professor Pattison said that his committee had considered the new information which had become available very carefully and had examined in detail all the possible options. ***The situation was that there were now nine cases of CJD which appeared to be different from classical CJD. There were, in addition, three other possibJe cases. The cases tended to be among the young but varied from those aged 18 to age 41. The new variant CJD showed. an atypical clinical picture with an unknown pathology. This had persuaded SEAC that the variant was distinct. No cases in the UK or abroad had been seen before which matched to this pattern. The Committee had considered the new methods of monitoring the occurrence of the disease and were aware lab techniques had improved, but they bad drawn the conclusion that they could not persuade themselves that it was more careful observation alone which had brought these cases to light.

 

This implied that there might be a new risk factor and in the view of the Committee the most likely explanation was that BSE was that risk factor. To date however the evidence was not available which proved that BSE could be linked to these cases. It appeared to the Committee to be the most likely explanation but they might be wrong. It might, for example, be that the new form had always been present in a low incidence but had remained unreported or there-might be an entirely separate new environmental factor. However, the committee was of the view that the most likely cause was something new in the cattle population in the mid-1980s which was causing something new in the human population in the mid-1990s. This was in their view likely to be exposure to BSE before the introduction of the SBO controls.

 

Professor Pattison noted that it was impossible to predict how many more cases there might be and it might well be eighteen months before the full extent of the problem could be ascertained. A dozen or so might be the limit or it might remain at a relatively low level as in cats and unlike in the cattle population it had not escalated. The cattle epidemic with escalating numbers was probably due to feeding cattle remains back to cattle. This had not happened with cats nor of course with humans.

 

The committee believed it was increasingly impossible to keep this information confidential. Members of the Committee had already had to attend two expert meetings where they had not been able to provide colleagues with the full story. Given the increasingly high risk of a leak it was the Committee's view that a controlled statement by the Government would be more appropriate. The Committee had considered whether extra restrictions on human consumption of beef or beef products would be necessary. They had not concluded that immediate measures were necessary other than to stress the importance of implementing existing controls as nearly perfectly as possible. The Committee would consider again at the weekend what more might be done. ranging from a do nothing option to the slaughter of the national herd.

 

Personally. Professor Pattison did not think that extreme measures would be necessary. In his view the committee was more likely to focus on controls concerning older cattle, together with further controls on mechanically recovered meat. ...snip...end...tss

 

96/03.19/16.2

 

CONFIDENTIAL – POLICY MARKET SENSITIVE - LIMITED DISTRIBUTION

 


 

CONFIDENTIAL – POLICY

 

SEAC

 

Since there were indications that the news was about to break, there was no reason to prevent all members of the Committee joining the meeting in London...

 


 

Sunday, July 06, 2014

 

Dietary Risk Factors for Sporadic Creutzfeldt-Jakob Disease: A Confirmatory Case-Control Study

 

Conclusions—The a priori hypotheses were supported.

 

*Consumption of various meat products may be one method of transmission of the infectious agent for sCJD.

 


 

Seven main threats for the future linked to prions

 

***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.

 

Second threat

 

snip...

 


 

Monday, October 10, 2011

 

EFSA Journal 2011 The European Response to BSE: A Success Story

 

snip...

 

*** but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.

 

snip...

 


 


 

***In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.

 


 

***Infectivity in skeletal muscle of BASE-infected cattle

 


 

***feedstuffs- It also suggests a similar cause or source for atypical BSE in these countries.

 


 

Friday, December 5, 2014

 

*** SPECIAL ALERT The OIE recommends strengthening animal disease surveillance worldwide ***

 

OIE BSE TSE PRION AKA MAD COW DISEASE ?

 

‘’the silence was deafening’’ ...tss

 


 

Wednesday, December 3, 2014

 

Over 200 Groups Urge Congress to Continue Supporting COOL

 

For Immediate Release

 


 

Tuesday, December 2, 2014

 

*** UK EXPORTS OF MBM TO WORLD Bovine Spongiform Encephalopathy BSE TSE Prion aka Mad Cow Disease

 

USA, NORTH AMERICA, MBM (or any potential TSE prion disease) EXPORTS TO THE WORLD (?) [protected by the BSE MRR policy] $$$

 


 

Monday, December 1, 2014

 

Germany Bovine Spongiform Encephalopathy BSE CJD TSE Prion disease A Review December 1, 2014

 


 

Friday, November 28, 2014

 

BOVINE SPONGIFORM ENCEPHALOPATHY BSE AKA MAD COW DISEASE PORTUGAL CONFIRMED

 


 

Sunday, October 5, 2014

 

France stops BSE testing for Mad Cow Disease

 


 

Monday, May 5, 2014

 

Brazil BSE Mad Cow disease confirmed OIE 02/05/2014

 


 

BSE INQUIRY DFAs

 


 

Sunday, May 18, 2008

 

BSE Inquiry DRAFT FACTUAL ACCOUNT DFA

 

BSE Inquiry DRAFT FACTUAL ACCOUNTS DFA's

 


 

Sunday, May 18, 2008

 

***BSE, CJD, and Baby foods (the great debate 1999 to 2005)

 


 

Sunday, May 18, 2008

 

***MAD COW DISEASE BSE CJD CHILDREN VACCINES

 


 

Sunday, December 7, 2014

 

Scientific update on the potential for transmissibility of non-prion protein misfolding diseases PRIONOIDS

 


 

Self-Propagative Replication of Ab Oligomers Suggests Potential Transmissibility in Alzheimer Disease

 

Received July 24, 2014; Accepted September 16, 2014; Published November 3, 2014

 

Singeltary comment ;

 


 

Saturday, December 13, 2014

 

Terry S. Singeltary Sr. Publications TSE prion disease

 

Diagnosis and Reporting of Creutzfeldt-Jakob Disease

 

Singeltary, Sr et al. JAMA.2001; 285: 733-734. Vol. 285 No. 6, February 14, 2001 JAMA

 

snip...

 


 

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY TSE PRION DISEASE

 


 

Terry S. Singeltary Sr. Bacliff, Texas USA 77518

No comments: